About this Journal Submit a Manuscript Table of Contents 
Mediators of Inflammation
Volume 2013 (2013), Article ID 591056, 9 pages
http://dx.doi.org/10.1155/2013/591056
Review Article

An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes

Alessandra Puddu,1 François Mach,2 Alessio Nencioni,1 Giorgio Luciano Viviani,1 and Fabrizio Montecucco2,3

1Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, Italy
2Division of Cardiology, Geneva University Hospitals, Faculty of Medicine, Foundation for Medical Researches, Avenue de la Roseraie 64, 1211 Geneva, Switzerland
3First Medical Clinic, Laboratory of Phagocyte Physiopathology and Inflammation, Department of Internal Medicine, University of Genoa, Viale Benedetto XV 6, 16132 Genoa, Italy

Received 8 October 2012; Revised 20 December 2012; Accepted 27 December 2012

Academic Editor: Dennis D. Taub

Copyright © 2013 Alessandra Puddu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Glucagon-like peptide-1 (GLP-1) is a gut hormone produced in the intestinal epithelial endocrine L cells by differential processing of the proglucagon gene. Released in response to the nutrient ingestion, GLP-1 plays an important role in maintaining glucose homeostasis. GLP-1 has been shown to regulate blood glucose levels by stimulating glucose-dependent insulin secretion and inhibiting glucagon secretion, gastric emptying, and food intake. These antidiabetic activities highlight GLP-1 as a potential therapeutic molecule in the clinical management of type 2 diabetes, (a disease characterized by progressive decline of beta-cell function and mass, increased insulin resistance, and final hyperglycemia). Since chronic hyperglycemia contributed to the acceleration of the formation of Advanced Glycation End-Products (AGEs, a heterogeneous group of compounds derived from the nonenzymatic reaction of reducing sugars with free amino groups of proteins implicated in vascular diabetic complications), the administration of GLP-1 might directly counteract diabetes pathophysiological processes (such as pancreatic β-cell dysfunction). This paper outlines evidence on the protective role of GLP-1 in preventing the deleterious effects mediated by AGEs in type 2 diabetes.

1. Introduction

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that participates to glucose homeostasis. In particular, it has been shown to efficiently lower glucose plasma concentration, improve insulin secretion and resistance, and preserve pancreatic beta-cell function [1, 2]. Due to these proprieties, GLP-1 has been suggested as a promising molecule for the treatment of type 2 diabetes (characterized by hyperglycemia and insulin resistance associated to a progressive deterioration of beta-cell function and mass) [3, 4]. Type 2 diabetes has been also described as a pathophysiological condition accelerating the formation and accumulation of advanced glycation end products (AGEs) that are normally produced with the aging processes [5, 6]. In fact, both repeated acute peaks and chronic hyperglycemia favor the nonenzymatic glycosylation of proteins, lipids, and nucleic acids that after rearrangement, dehydration, and condensation become irreversibly cross-linked, heterogeneous fluorescent derivatives called AGEs. The glycation of these molecules induces alterations in their biological properties as compared with the nonglycated counterparts. Moreover, the binding between AGEs and their receptor (RAGE) provokes oxidative stress generation and inflammatory burst [7]. The pathogenic role of AGEs in microvascular complications of type 2 diabetes is widely investigated and recognized. Recently, some novel detrimental effects of AGEs in type 2 diabetes have been also identified (i) interference by AGEs with the complex molecular pathway of insulin signaling, leading to insulin resistance; (ii) AGE-mediated modification of the insulin molecular structure and function; (iii) AGE-induced decrease insulin secretion and production. Since molecular alterations induced by AGEs are “permanent”, these products have been suggested as key mediators in the “metabolic memory” hypothesis, explaining how diabetic complications are evolving even after glucose control is achieved. In this paper, we will discuss evidence on the protective role of GLP-1 in preventing the deleterious effects of AGEs in type 2 diabetes.

2. GLP-1 Production and Secretion

GLP-1 was firstly identified and characterized following the cloning of cDNAs and genes for proglucagon in the early 1980s [8–10]. The major sources of GLP-1 in the body are the intestinal L cells, open-type intestinal epithelial endocrine cells located mainly in the distal ileum and colon, which secrete GLP-1 as a gut hormone [11]. GLP-1 derives from the transcription product of the proglucagon gene which is expressed in the pancreas, intestine, and brain. The proglucagon mRNA is translated into a single-precursor protein that undergoes tissue-specific posttranslational processing operated by prohormone convertase (PC) isoforms, which leads to the synthesis of different proglucagon-derived peptides in the pancreatic α-cells and in the intestinal L-cells. Indeed expression of PC 2 in α cells leads to synthesis of glucagon, glicentin-related pancreatic peptide, and the major proglucagon fragment, which contains within its sequence both GLP-1 and GLP-2; while expression of PC 1/3 in enteroendocrine L cells results in the production of GLP-1 and GLP-2, as well as glicentin and oxyntomodulin [11]. The prohormone convertase PC1/3 has been localized in intestinal L cells and shown to be both necessary and sufficient for posttranslational processing of proglucagon in the intestine. Indeed, PC1/3 null mice exhibit impaired processing of the precursor with accumulation of intestinal proglucagon coupled to marked decreases in proglucagon processing to glicentin, oxyntomodulin, GLP-1, and GLP-2 [12].

The biologically active forms of GLP-1 released in the blood stream are GLP-1(7–36) and GLP-1(7–37), which result from the selective cleavage of the proglucagon molecule [13] and appear equipotent in all biological paradigms studied [14]. In humans, the majority of GLP-1 in the circulation is GLP-1(7–36)NH2. The enzyme peptidylglycine α-amidating monooxygenase operates the addition of an amide group to GLP-1(1–36) and GLP-1(7–36) to enhance the survival of GLP-1 in plasma [13, 15]. Indeed, the half-life of bioactive GLP-1 in the circulation is less than 2 minutes due to a rapid inactivation by the ubiquitous proteolytic enzyme dipeptidyl peptidase-4 (DPP-4), that cleaves GLP-1 at the N-terminal (GLP-1 9–36) [16, 17].

Accordingly to the position of the L cells (which directly contact the luminal nutrients through their apical surface), GLP-1 secretion is stimulated by a variety of nutrients [18, 19]. Furthermore, the basolateral surface of L cells is located in close proximity to both neurons and the microvasculature of the intestine, which allows the L cell to be affected by both neural and hormonal signals. The mean levels of bioactive GLP-1 in fasting plasma range between 5 and 10 pmol/L in humans and increase approximately 2- to 3-fold after a meal, with the absolute peak values being dependent on both the size and nutrient composition of the meal. Food intake is the primary physiological stimulus to GLP-1 secretion by L cells and results in a biphasic pattern: an initial rapid rise in circulating GLP-1 levels within 15–30 min after a meal, followed by a late minor peak up to 90–120 min [20].

3. Intra- and Extrapancreatic Activities of GLP-1

GLP-1 plays multiple roles in metabolic homeostasis following nutrient absorption. One of the first actions identified for GLP-1 was the glucose-dependent stimulation of insulin secretion from islets in rodents, humans, or from islet cell lines [21–24]. GLP-1 induces additional actions in the gastrointestinal tract and central nervous system [25, 26], such as the promotion of insulin biosynthesis, reduction of gluconeogenesis rate, inhibition of glucagon secretion and gastric emptying, and reduction of food intake. The biological effects of GLP-1 are mediated by the binding to its specific receptor (GLP-1R, a specific seven-transmembrane receptor guanine nucleotide-binding protein [G-protein] coupled receptor [GPCR]). GLP-1R was firstly cloned from a rat pancreatic islet library by Thorens in 1992 [27]. The receptor is widely distributed in the pancreatic islets, brain, heart, kidney, and the gastrointestinal tract and mediates the biological actions of GLP-1 in a variety of tissues.

The bioactivities of GLP-1 were investigated mainly in the pancreatic islets. In the pancreas, GLP-1 potentiates glucose-induced insulin secretion improves the function of pancreatic β-cells by promoting the genesis and proliferation and by inhibiting apoptotic signals and glucagon secretion from pancreatic α-cells, thus resulting in the regulation of glucose homeostasis [28]. GLP-1 synergistically acts with glucose to promote insulin gene transcription, mRNA stability, and biosynthesis, increasing the expression of the transcription factor Pancreas duodenum homeobox 1 (Pdx-1) and the binding of Pdx-1 to the insulin promoter. Furthermore, GLP-1 has been shown to improve glucose sensitivity to glucose-resistant β cells [29–31].

In the gastrointestinal system, GLP-1 has been shown to enhance satiety and the feeling of “fullness” delaying gastric emptying, and to inhibit food intake [32–34]. In isolated primary rat hepatocytes and skeletal muscle cells, GLP-1 increases glucose incorporation into glycogen and enhances insulin-stimulated glucose metabolism in adipocytes [35–37]. GLP-1 also inhibits hepatic glucose production and stimulates glucose uptake in fat and muscle and increases glycogen synthase activity and glucose metabolism in skeletal muscle. GLP-1 has been also suggested to induce beneficial effects in the cardiovascular systems, such as some improvements in blood pressure, vascular tone, and myocardial function [38]. There is also increasing evidence from animal models to support a potential role for GLP-1 in neuroprotection, and the increased risk of developing neurodegenerative conditions such as Alzheimer’s disease and Parkinson’s disease in patients with T2DM suggests that there may be shared underlying mechanisms in these conditions [39].

Impaired GLP-1 physiology is one of several known metabolic deficiencies involved in T2DM. Although controversial data have been reported [40], some studies showed that postprandial levels of intact, biologically active GLP-1 are reduced in obese and type 2 diabetic individuals [41–43]. Despite the reduction of GLP-1 secretion, the glucose-lowering action of GLP-1 are preserved in patients with type 2 diabetes [44, 45], as well as the actions of GLP-1 on inhibition of gastric emptying [46]. On the basis of these findings the augmenting GLP-1 signaling became a useful strategy for treatment of diabetic patients.

The key limitation to the therapeutic use of GLP-1 is represented by its rapid inactivation. To avoid this problem, DPP-4 inhibitors (such as sitagliptin, vidagliptin, or saxagliptin, which stabilize endogenous GLP-1), and more stable exogenous molecules which act as GLP1R agonists (such as the GLP-1 mimetic exenatide, or the human GLP-1 analogue liraglutide) have been used [47–50]. DPP-4 inhibition produces approximately a doubling of the circulating GLP-1 levels, while synthetic agonists mimicking GLP-1 action results in striking elevations of GLP-1 signaling [3, 51–56].

4. Formation of AGEs

AGEs are a heterogeneous group of structures formed as both cross- and noncross-linking adducts on proteins, lipids, and nucleic acids [6].

In the last century, a nonenzymatic reaction (glycation, underlying AGE formation) was firstly described by Maillard [57]. The Maillard reaction is characterized by the interaction of carbonyl group (aldehyde or ketone) of a reducing sugar with free amino groups of proteins, amino acids, phospholipids, and nucleic acids. The reaction starts with the reversible formation of a Schiff base between a reducing sugar and the amino group of a protein. Under hyperglycemic and/or oxidative stress conditions the relatively unstable Schiff base rearranges to form a more stable Amadori product. Depending on the protein turnover rate and on the glucose concentration, Amadori products undergo further irreversible reactions to form AGEs [58, 59]. The rate and direction of the Maillard reaction may be affected by many others factors, such as the initial pH of the products, the buffer capacity of the system, the temperature and heating time, the moisture content, the nature of the reactants (low molecular weight compounds tend to be more reactive than high molecular weight compounds due to greater steric encumbrance), and the nature of the amino compound (e.g., lysine is more reactive than other amino acids due to the presence of the ε-amino group). Besides endogenous formation through the Maillard reaction, AGEs can be also generated from exogenous substances, such as smoke and food. Reactive and toxic glycation products released by combustion of tobacco enter the blood stream and accumulate in the tissues through the lung capillary network [60]. High levels of AGEs are also generated by heating during food preparation and are then absorbed by the intestinal epithelium [61]. Dietary AGEs have a low bioavailability (average 10%), however more than 70% of them were found linked to proteins or incorporated in tissues with consequently injurious impact to vascular and kidney tissues [62].

AGEs are continuously formed and removed in different tissues and body fluids. Formation of AGEs involved modification of long-lived proteins, such as albumin and collagen both in healthy and in diabetic subjects. The mechanism of AGE-mediated cellular damage is a complex process which can be related to chemical modification and cross-linking of tissue proteins, lipids and DNA, and/or mediated by the interaction with specific receptors [63]. The formation and accumulation of AGEs may lead to the modification of intracellular molecules, including most importantly proteins involved in the regulation of gene transcription. Furthermore, the adducts formed as DNA-bound AGEs can affect expression of DNA or even induce permanent mutation. AGEs can also modify extracellular matrix molecules changing signaling between the matrix and the cell, thus causing cellular dysfunction. AGE-modified circulating proteins can bind to AGE receptors, which may have a role in both AGE detoxification and suppression of oxidative stress and inflammation [64, 65]. Therefore, self-maintaining conditions linked to AGE formation would be conceivable as contributing to the so-called “metabolic memory” [66].

5. AGEs Activate Injury Pathways in Diabetic Pathophysiology

The key role of AGEs in the onset and evolution of diabetic complications is widely recognized. Several studies reported that the activation of RAGE by AGEs induces the production of inflammatory cytokines and growth factors, which in turn cause vascular pathology [67, 68]. A causal relationship between the markers of early and advanced glycation with diabetic complications has been established in both type 1 and 2 diabetes in basic research and clinical studies [5, 67, 69–71].

In the last decade, a direct role of AGEs on pancreatic β cell dysfunction in diabetic pathogenesis was also shown [72–76]. The exposure of pancreatic β cells to AGEs increased oxidative stress, and contemporarily decreased the already low levels of antioxidant activity [73, 77]. Oxidative stress has been implicated not only in cellular injury, but also in cell death, and the AGEs impaired pancreatic β-cell viability was reported in different cell lines [73, 74, 78–80]. Furthermore, AGEs decrease insulin production and release in response to glucose. This events was associated with a decreased expression of PDX-1 (one of the main positive regulators of insulin gene transcription) [72, 81]. Furthermore, we showed that AGEs altered the subcellular localization of transcription factors involved in insulin gene expression. Although the mechanisms of AGE-induced pancreatic β-cell dysfunction have to be further clarified, evidence indicates that AGEs interfere with several steps of the insulin-mediated regulation of glucose: AGEs inhibit the production of ATP needed for insulin secretion and decrease the expression of proteins involved in exocytosis of the insulin granules. Moreover, it has been demonstrated that glycation of insulin occurs during diabetes, and that glycated insulin represents a significant proportion of total circulating insulin in type 2 diabetes [82, 83]. Animal studies using isolated muscle and adipose tissue suggest that insulin glycation is associated with a significant compromise of its biological activity. This aspect raises the possibility that insulin glycation might contribute to insulin resistance and glucose intolerance in type 2 diabetes [84, 85]. Besides insulin glycation AGEs may contribute to insulin-resistance at least with two additional mechanisms: (1) evidence that AGE-modified proteins disturb insulin bioactivities in cultured adipocytes and skeletal muscles; (2) impairment of insulin receptor substrate signaling.

These data clearly indicate that the prevention of the synthesis and tissue accumulation of AGE- or oxidative-derived end-products might represent a major advance in the treatment of diabetic complications. Several compounds with putative properties against AGE accumulation have been investigated in both clinical and experimental settings, but in most cases the results were disappointing or inferior to benefits expected [86–90].

6. GLP-1 Reduces Expression of RAGE

During the last decade, the promising therapeutic role of GLP-1 to prevent AGE-induced damage was preliminary investigated with encouraging results. Several cell types (such as endothelial cells [91–94], mesangial, neuronal, and pancreatic beta cells [77, 95, 96]) were used in vitro at this purpose.

These studies showed that the interaction between AGEs and RAGE evoked reactive oxygen specie (ROS) generation, eliciting vascular inflammation and thrombosis (conditions described in the diabetic vascular complications). Thus, stopping the vicious cycle triggered by RAGE ligand-RAGE pathway would be helpful to improve the maladaptive effects of glucose in diabetes. Evidence that GLP-1 may be efficient in reducing RAGE expression came out in 2010, when Ishibashi and coworkers demonstrated that GLP-1 dose-dependently decreases constitutive RAGE mRNA levels in an endothelial cell line. In particular, both RAGE mRNA and protein levels were abrogated to about 70% of control cells [91]. Furthermore, authors showed that GLP-1 suppressed the downstream signaling evoked by interaction between AGEs and RAGE and also AGE-induced VCAM-1 expression. One year later, the same group demonstrated in human mesangial cells that GLP-1 decreased RAGE mRNA and protein levels to about 80% of control cells [96]. GLP-1 was able to block the downstream signaling pathway of AGEs-RAGE axis also in these cells, as confirmed by the inhibition of AGE-induced MCP-1 expression. In the same year, Matsui et al. [93] investigated the effects of Vildagliptin, a stable inhibitor of dipeptidyl peptidase-IV, on attenuation of RAGE expression in thoracic aorta of an animal model of type 2 diabetes with obesity, the Otsuka Long-Evans Tokushima Fatty rats (OLETF rats). Quantitative real-time RT-PCR and immunohistochemical analyses revealed that treatment with vildagliptin completely abrogated the increased expression of RAGE mRNA and protein in OLETF rats. Furthermore, vildagliptin blocked the RAGE-downstream pathways in the aorta of OLETF rats, thus preventing the upregulation of two membrane components of NADPH oxidase, gp91phox and p22phox and, subsequently, reducing 8-OHdG level, a marker of oxidative stress generation in the thoracic aorta of OLETF rats. Treatment with Vildagliptin also decreased the accumulation of AGEs in the thoracic aorta of OLETF rats, as revealed by immunohistochemical analyses. Ishibashi et al. demonstrated that Sitagliptin, another stable inhibitor of dipeptidyl peptidase-IV, in combination with 10 pM GLP-1 completely blocked the AGE-induced increase in RAGE mRNA and protein levels in human umbilical vein endothelial cells [92]. Accordingly, in HIT-T15 cells, we demonstrated that GLP-1 counteracted AGE-induced expression of RAGE mRNA, thus attenuating the detrimental effects of AGEs [77]. Interestingly, it has been reported that analogous of cyclic AMP (cAMP) mimicked the effects of GLP-1 on RAGE gene expression in both mesangial and endothelial cells [91, 96]. Since the biological activity of GLP-1 is mainly mediated by the cAMP pathway, the ability of GLP-1 in reducing RAGE expression may be related to a cAMP-dependent pathway activated by GLP-1R.

7. GLP-1 Reduces AGE-Induced Oxidative Stress

There is growing body of evidence that AGE-RAGE interaction might provoke oxidative stress generation and inflammation, thereby causing progressive loss of cell function. The restoration of the redox status can lead to the attenuation of the AGE-induced injury and may be achieved through the inhibition of ROS production and/or through the increased expression of antioxidant enzymes. It has been reported that GLP-1 counteracts the AGE-induced ROS generation in many cell cultures [77, 91, 92]. In this context, glutathione might play an important role in the cellular defense against oxidant aggression and in maintaining redox homeostasis. Considering that an increased ratio between the oxidized (GSSG) and the reduced form (GSH) are directly associated with oxidative stress, we found that AGEs increased GSSG to GSH ratio rising the levels of GSSG and reducing in the same time the availability of GSH in a pancreatic beta-cell line [77]. Interestingly, GLP-1 restored the levels of GSH, without affecting GSSG, suggesting that the protective effect of GLP-1 on oxidative stress is mainly related to its ability of increasing antioxidant defense [77]. The same behavior has been observed in neuronal cells [95].

8. GLP-1 Prevents AGE-Induced Cell Death

GLP-1 has been shown to prevent AGE-impaired viability in many cell types [77, 94, 95]. This important effect is related to the reduction of oxidative stress and alteration of Bcl-2- and caspase-mediated pathways [73, 77, 94]. Recently, we demonstrated in pancreatic beta cells that GLP-1 was able to prevent AGE-induced necrosis and apoptosis and that this condition is related to a decreased caspase-3 activity [77]. Kimura and coworkers showed that GLP-1 protected neuronal cells against methylglyoxal-induced apoptosis, and that certain signaling pathways (such as PI3 K/Akt/mTOR/GCLc/redox, cyclic AMP (cAMP), and MAPK) have a crucial role in the beneficial effects mediated by GLP-1 [95]. Zhan and coworkers showed that GLP-1 attenuated AGE-mediated proapoptotic activities in endothelial cells by the release of cytochrome c, increased expression of the proapoptotic protein Bax, and caspase activation. Taken together, these findings suggest that cAMP might be actively involved in the AGE-triggered signaling pathways. In particular, in human umbilical vein endothelial cells (HUVEC) exposed to AGEs, RAGE might be a critical molecular target that is selectively reduced by the protective pathways activated by GLP1R.

9. Conclusion

Inhibitory treatments targeting the accumulation of AGEs may have beneficial effects on the development/progression of diabetic complications and may protect pancreatic β cells from the deleterious effects of the diabetic milieu. In this paper, we highlighted evidence that GLP-1 may counteract AGE-induced damage, preserving the pancreatic β-cell function, limiting the disease progression and the development of its vascular complications. These beneficial effects may be attributable not only to the improvement of the glycaemic control (leading to a slowing down in the accumulation of AGEs), but also to the blockage of the AGEs-RAGE axis, which is a pathogenetic mechanism of diabetes and its complications. Despite ameliorating hyperglycaemia, GLP-1 might provide different levels of protection from the deleterious effects of AGEs: (i) by increasing antioxidant defence, thereby reducing cellular stress; (ii) by blocking the positive feedback of AGEs on RAGE expression (Figures 1 and 2).

591056.fig.001
Figure 1: Beneficial effects of GLP-1 in pancreatic beta cells exposed to AGEs. The activation of the AGEs-RAGE axis in pancreatic beta cells increases oxidative stress that causes mitochondrial dysfunction, endoplasmic reticulum stress, and altered signal transduction. These detrimental effects modify gene expression leading to increased expression of RAGE and proapoptotic molecules, and downregulation of proteins involved in insulin gene expression, such as PDX-1, thus causing decreased insulin production and loss of glucose-stimulated insulin secretion (GSIS). Activation of GLP-1 signaling increases antioxidant defense thus counteracting formation of reactive oxygen species (ROS) and expression of RAGE, blocking the positive feedback loop that links RAGE activation with RAGE expression. Furthermore, GLP-1 maintaining pancreatic beta-cell function restores GSIS, thus contributing to reduce plasma glucose concentration and, consequently, formation of new AGEs.
591056.fig.002
Figure 2: Beneficial effects of GLP-1 in other cells exposed to AGEs. Detrimental effect of AGEs leads to cell dysfunction and, eventually, cell death. GLP-1, counteracting AGEs-induced damage with mechanisms reported in pancreatic beta cells, may contribute to reducing diabetic complications.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgments

Dr. G. L. Viviani and Dr. F. Montecucco equally contributed as last authors to this work. This research was funded by EU FP7, Grant no. 201668, AtheroRemo to Dr. F. Mach. This work was also supported by the Swiss National Science Foundation Grants to Dr. F. Mach (no. 310030-118245) and Dr. F. Montecucco (no. 32003B-134963/1). This work was funded by a Grant from Novartis Foundation to Dr. F. Montecucco.

References

  1. J. J. Holst, “The physiology of glucagon-like peptide 1,” Physiological Reviews, vol. 87, no. 4, pp. 1409–1439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. J. Garber, “Incretin effects on beta-cell function, replication, and mass: the human perspective,” Diabetes Care, vol. 34, supplement 2, pp. S258–S263, 2011. View at Scopus
  3. S. A. Ross and J. M. Ekoé, “Incretin agents in type 2 diabetes,” Canadian Family Physician, vol. 56, no. 7, pp. 639–648, 2010. View at Scopus
  4. D. J. Drucker and M. A. Nauck, “The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes,” Lancet, vol. 368, no. 9548, pp. 1696–1705, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Meerwaldt, T. Links, C. Zeebregts, R. Tio, J. L. Hillebrands, and A. Smit, “The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes,” Cardiovascular Diabetology, vol. 7, article no. 29, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Singh, A. Barden, T. Mori, and L. Beilin, “Advanced glycation end-products: A review,” Diabetologia, vol. 44, no. 2, pp. 129–146, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. S. F. Yan, R. Ramasamy, and A. M. Schmidt, “The RAGE axis a fundamental mechanism signaling danger to the vulnerable vasculature,” Circulation Research, vol. 106, no. 5, pp. 842–853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. P. K. Lund, R. H. Goodman, and J. F. Habener, “Intestinal glucagon mRNA identified by hybridization to a cloned islet cDNA encoding a precursor,” Biochemical and Biophysical Research Communications, vol. 100, no. 4, pp. 1659–1666, 1981. View at Scopus
  9. P. K. Lund, R. H. Goodman, P. C. Dee, and J. F. Habener, “Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 2 I, pp. 345–349, 1982. View at Scopus
  10. P. K. Lund, R. H. Goodman, and M. R. Montminy, “Anglerfish islet pre-proglucagon II: Nucleotide and corresponding amino acid sequence of the cDNA,” Journal of Biological Chemistry, vol. 258, no. 5, pp. 3280–3284, 1983. View at Scopus
  11. T. J. Kieffer and J. F. Habener, “The glucagon-like peptides,” Endocrine Reviews, vol. 20, no. 6, pp. 876–913, 1999. View at Scopus
  12. R. Ugleholdt, X. Zhu, C. F. Deacon, C. Ørskov, D. F. Steiner, and J. J. Holst, “Impaired Intestinal Proglucagon Processing in Mice Lacking Prohormone Convertase 1,” Endocrinology, vol. 145, no. 3, pp. 1349–1355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Orskov, L. Rabenhoj, A. Wettergren, H. Kofod, and J. J. Holst, “Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans,” Diabetes, vol. 43, no. 4, pp. 535–539, 1994. View at Scopus
  14. C. Orskov, A. Wettergren, and J. J. Holst, “Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable,” Diabetes, vol. 42, no. 5, pp. 658–661, 1993. View at Scopus
  15. A. Martinez, M. A. Burrell, M. Kuijk et al., “Localization of amidating enzymes (PAM) in rat gastrointestinal tract,” Journal of Histochemistry and Cytochemistry, vol. 41, no. 11, pp. 1617–1622, 1993. View at Scopus
  16. C. F. Deacon, M. A. Nauck, M. Toft-Nielsen, L. Pridal, B. Willms, and J. J. Holst, “Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects,” Diabetes, vol. 44, no. 9, pp. 1126–1131, 1995. View at Scopus
  17. A. M. Lambeir, C. Durinx, S. Scharpé, and I. De Meester, “Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV,” Critical Reviews in Clinical Laboratory Sciences, vol. 40, no. 3, pp. 209–294, 2003. View at Scopus
  18. C. Herrmann, R. Goke, G. Richter, H. C. Fehmann, R. Arnold, and B. Goke, “Glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide plasma levels in response to nutrients,” Digestion, vol. 56, no. 2, pp. 117–126, 1995. View at Scopus
  19. R. M. Elliott, L. M. Morgan, J. A. Tredger, S. Deacon, J. Wright, and V. Marks, “Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: Acute post-prandial and 24-h secretion patterns,” Journal of Endocrinology, vol. 138, no. 1, pp. 159–166, 1993. View at Scopus
  20. E. Rask, T. Olsson, S. Söderberg et al., “Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men,” Diabetes Care, vol. 24, no. 9, pp. 1640–1645, 2001. View at Scopus
  21. D. J. Drucker, J. Philippe, and S. Mojsov, “Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 10, pp. 3434–3438, 1987. View at Scopus
  22. J. J. Holst, C. Orskov, O. V. Nielsen, and T. W. Schwartz, “Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut,” FEBS Letters, vol. 211, no. 2, pp. 169–174, 1987. View at Scopus
  23. B. Kreymann, G. Williams, M. A. Ghatei, and S. R. Bloom, “Glucagon-like peptide-1 7-36: A physiological incretin in man,” Lancet, vol. 2, no. 8571, pp. 1300–1304, 1987. View at Scopus
  24. S. Mojsov, G. C. Weir, and J. F. Habener, “Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas,” Journal of Clinical Investigation, vol. 79, no. 2, pp. 616–619, 1987. View at Scopus
  25. D. J. Drucker, “Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes,” Current Pharmaceutical Design, vol. 7, no. 14, pp. 1399–1412, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. D. J. Drucker, “Biological actions and therapeutic potential of the glucagon-like peptides,” Gastroenterology, vol. 122, no. 2, pp. 531–544, 2002. View at Scopus
  27. B. Thorens, “Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 18, pp. 8641–8645, 1992. View at Scopus
  28. D. J. Drucker, “Enhancing incretin action for the treatment of type 2 diabetes,” Diabetes Care, vol. 26, no. 10, pp. 2929–2940, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Farilla, A. Bulotta, B. Hirshberg et al., “Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets,” Endocrinology, vol. 144, no. 12, pp. 5149–5158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. P. E. MacDonald, W. El-kholy, M. J. Riedel, A. M. F. Salapatek, P. E. Light, and M. B. Wheeler, “The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion,” Diabetes, vol. 51, supplement 3, pp. S434–S442, 2002. View at Scopus
  31. G. Xu, D. A. Stoffers, J. F. Habener, and S. Bonner-Weir, “Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats,” Diabetes, vol. 48, no. 12, pp. 2270–2276, 1999. View at Scopus
  32. J. P. Gutzwiller, B. Göke, J. Drewe et al., “Glucagon-like peptide-1: A potent regulator of food intake in humans,” Gut, vol. 44, no. 1, pp. 81–86, 1999. View at Scopus
  33. S. Delgado-Aros, D. Y. Kim, D. D. Burton et al., “Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans,” American Journal of Physiology, vol. 282, no. 3, pp. G424–G431, 2002. View at Scopus
  34. J. J. Meier, B. Gallwitz, W. E. Schmidt, and M. A. Nauck, “Glucagon-like peptide 1 as a regulator of food intake and body weight: Therapeutic perspectives,” European Journal of Pharmacology, vol. 440, no. 2-3, pp. 269–279, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. J. M. Egan, C. Montrose-Rafizadeh, Y. Wang, M. Bernier, and J. Roth, “Glucagon-like peptide-1 (7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: One of several potential extrapancreatic sites of GLP-1 action,” Endocrinology, vol. 135, no. 5, pp. 2070–2075, 1994. View at Publisher · View at Google Scholar · View at Scopus
  36. M. A. Luque, N. González, L. Márquez et al., “Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes,” Journal of Endocrinology, vol. 173, no. 3, pp. 465–473, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Perea, C. Viñambres, F. Clemente, M. L. Villanueva-Peñacarrillo, and I. Valverde, “GLP-1 (7-36) amide: Effects on glucose transport and metabolism in rat adipose tissue,” Hormone and Metabolic Research, vol. 29, no. 9, pp. 417–421, 1997. View at Scopus
  38. R. Abu-Hamdah, A. Rabiee, G. S. Meneilly, R. P. Shannon, D. K. Andersen, and D. Elahi, “The extrapancreatic effects of glucagon-like peptide-1 and related peptides,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 6, pp. 1843–1852, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Holscher, “Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection,” CNS Drugs, vol. 26, no. 10, pp. 871–882, 2012. View at Publisher · View at Google Scholar
  40. K. Vollmer, J. J. Hoist, B. Bailer et al., “Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance,” Diabetes, vol. 57, no. 3, pp. 678–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Nauck, F. Stockmann, R. Ebert, and W. Creutzfeldt, “Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes,” Diabetologia, vol. 29, no. 1, pp. 46–52, 1986. View at Scopus
  42. M. B. Toft-Nielsen, M. B. Damholt, S. Madsbad et al., “Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 8, pp. 3717–3723, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Vilsbøll, T. Krarup, C. F. Deacon, S. Madsbad, and J. J. Holst, “Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients,” Diabetes, vol. 50, no. 3, pp. 609–613, 2001. View at Scopus
  44. M. A. Nauck, M. M. Heimesaat, C. Orskov, J. J. Holst, R. Ebert, and W. Creutzfeldt, “Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus,” Journal of Clinical Investigation, vol. 91, no. 1, pp. 301–307, 1993. View at Scopus
  45. D. Elahi, M. McAloon-Dyke, N. K. Fukagawa et al., “The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects,” Regulatory Peptides, vol. 51, no. 1, pp. 63–74, 1994. View at Publisher · View at Google Scholar · View at Scopus
  46. B. Willms, J. Werner, J. J. Holst, C. Ørskov, W. Creutzfeldt, and M. A. Nauck, “Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (Noninsulin-Dependent) diabetic patients,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 1, pp. 327–332, 1996. View at Scopus
  47. L. K. Phillips and J. B. Prins, “Update on incretin hormones,” Annals of the New York Academy of Sciences, vol. 1243, pp. E55–E74, 2011. View at Publisher · View at Google Scholar
  48. F. K. Knop, T. Vilsbøll, and J. J. Holst, “Incretin-based therapy of type 2 diabetes mellitus,” Current Protein and Peptide Science, vol. 10, no. 1, pp. 46–55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Vilsbøll and F. K. Knop, “Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus,” BioDrugs, vol. 22, no. 4, pp. 251–257, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. E. J. Verspohl, “Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors,” Pharmacology and Therapeutics, vol. 124, no. 1, pp. 113–138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Ahrén, M. Landin-Olsson, P. A. Jansson, M. Svensson, D. Holmes, and A. Schweizer, “Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 5, pp. 2078–2084, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. H. C. Fehmann, J. Jiang, J. Schweinfurth, M. B. Wheeler, A. E. Boyd, and B. Goke, “Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39),” Peptides, vol. 15, no. 3, pp. 453–456, 1994. View at Publisher · View at Google Scholar · View at Scopus
  53. G. A. Herman, C. Stevens, K. Van Dyck et al., “Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses,” Clinical Pharmacology and Therapeutics, vol. 78, no. 6, pp. 675–688, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Goke, H. C. Fehmann, T. Linn et al., “Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells,” Journal of Biological Chemistry, vol. 268, no. 26, pp. 19650–19655, 1993. View at Scopus
  55. L. B. Knudsen, P. F. Nielsen, P. O. Huusfeldt et al., “Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration,” Journal of Medicinal Chemistry, vol. 43, no. 9, pp. 1664–1669, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Mari, W. M. Sallas, Y. L. He et al., “Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 8, pp. 4888–4894, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. F. J. Tessier, “The Maillard reaction in the human body. The main discoveries and factors that affect glycation,” Pathologie Biologie, vol. 58, no. 3, pp. 214–219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. V. M. Monnier, “Nonenzymatic glycosylation, the Maillard reaction and the aging process,” Journals of Gerontology, vol. 45, no. 4, pp. B105–B111, 1990. View at Scopus
  59. D. G. Dyer, J. A. Blackledge, B. M. Katz et al., “The Maillard reaction in vivo,” Zeitschrift fur Ernahrungswissenschaft, vol. 30, no. 1, pp. 29–45, 1991. View at Scopus
  60. C. Cerami, H. Founds, I. Nicholl et al., “Tobacco smoke is a source of toxic reactive glycation products,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 25, pp. 13915–13920, 1997. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Vlassara, W. Cai, J. Crandall et al., “Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15596–15601, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Uribarri, W. Cai, O. Sandu, M. Peppa, T. Goldberg, and H. Vlassara, “Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects,” Annals of the New York Academy of Sciences, vol. 1043, pp. 461–466, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. A. M. Schmidt, S. D. Yan, S. F. Yan, and D. M. Stern, “The biology of the receptor for advanced glycation end products and its ligands,” Biochimica et Biophysica Acta, vol. 1498, no. 2-3, pp. 99–111, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Vlassara, “The AGE-receptor in the pathogenesis of diabetic complications,” Diabetes/Metabolism Research and Reviews, vol. 17, no. 6, pp. 436–443, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Ceriello, “The emerging challenge in diabetes: the ‘metabolic memory’,” Vascular Pharmacology, vol. 57, no. 5-6, pp. 133–138, 2012. View at Publisher · View at Google Scholar
  67. N. Ahmed and P. J. Thornalley, “Advanced glycation endproducts: What is their relevance to diabetic complications?” Diabetes, Obesity and Metabolism, vol. 9, no. 3, pp. 233–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Brownlee, “The pathobiology of diabetic complications: A unifying mechanism,” Diabetes, vol. 54, no. 6, pp. 1615–1625, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Prasad, P. Bekker, and S. Tsimikas, “Advanced glycation end products and diabetic cardiovascular disease,” Cardiology in Review, vol. 20, no. 4, pp. 177–183, 2012. View at Publisher · View at Google Scholar
  70. R. Ramasamy, S. F. Yan, and A. M. Schmidt, “Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications,” Annals of the New York Academy of Sciences, vol. 1243, pp. 88–102, 2011. View at Publisher · View at Google Scholar
  71. H. Zong, M. Ward, and A. W. Stitt, “AGEs, RAGE, and diabetic retinopathy,” Current Diabetes Reports, vol. 11, no. 4, pp. 244–252, 2011. View at Publisher · View at Google Scholar
  72. A. Puddu, D. Storace, P. Odetti, and G. L. Viviani, “Advanced glycation end-products affect transcription factors regulating insulin gene expression,” Biochemical and biophysical research communications, vol. 395, no. 1, pp. 122–125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. G. Luciano Viviani, A. Puddu, G. Sacchi et al., “Glycated fetal calf serum affects the viability of an insulin-secreting cell line in vitro,” Metabolism: Clinical and Experimental, vol. 57, no. 2, pp. 163–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Lim, L. Park, G. Shin, H. Hong, I. Kang, and Y. Park, “Induction of apoptosis of β cells of the pancreas by advanced glycation end-products, important mediators of chronic complications of diabetes mellitus,” Annals of the New York Academy of Sciences, vol. 1150, pp. 311–315, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. Q. M. Ge, Y. Dong, and Q. Su, “Effects of glucose and advanced glycation end products on oxidative stress in MIN6 cells,” Cellular and Molecular Biology, vol. 56, supplement 1, pp. OL1231–OL1238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. Z. Zhao, C. Zhao, H. Z. Xu et al., “Advanced glycation end products inhibit glucose-stimulated insulin secretion through nitric oxide-dependent inhibition of cytochrome c oxidase and adenosine triphosphate synthesis,” Endocrinology, vol. 150, no. 6, pp. 2569–2576, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Puddu, D. Storace, A. Durante, P. Odetti, and G. L. Viviani, “Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15,” Biochemical and Biophysical Research Communications, vol. 398, no. 3, pp. 462–466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Minakawa, A. Kawano, Y. Miura, and K. Yagasaki, “Hypoglycemic effect of resveratrol in type 2 diabetic model db/db mice and its actions in cultured L6 myotubes and RIN-5F pancreatic β-cells,” Journal of Clinical Biochemistry and Nutrition, vol. 48, no. 3, pp. 237–244, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Dhar, I. Dhar, B. Jiang, K. M. Desai, and L. Wu, “Chronic methylglyoxal infusion by minipump causes pancreatic β-cell dysfunction and induces type 2 diabetes in Sprague-Dawley rats,” Diabetes, vol. 60, no. 3, pp. 899–908, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. Y. Zhu, T. Shu, Y. Lin et al., “Inhibition of the receptor for advanced glycation endproducts (RAGE) protects pancreatic β-cells,” Biochemical and Biophysical Research Communications, vol. 404, no. 1, pp. 159–165, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Shu, Y. Zhu, H. Wang, Y. Lin, Z. Ma, and X. Han, “Ages decrease insulin synthesis in pancreatic β-cell by repressing pdx-1 protein expression at the post-translational level,” PLoS ONE, vol. 6, no. 4, Article ID e18782, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. A. M. McKillop, Y. H. A. Abdel-Wahab, M. H. Mooney, F. P. M. O'Harte, and P. R. Flatt, “Secretion of glycated insulin from pancreatic β-cells in diabetes represents a novel aspect of β-cell dysfunction and glucose toxicity,” Diabetes and Metabolism, vol. 28, no. 6, pp. 3–S61, 2002. View at Scopus
  83. A. M. McKillop, J. R. Lindsay, S. Au et al., “Meal-dependent regulation of circulating glycated insulin in type 2 diabetic subjects,” Hormone and Metabolic Research, vol. 38, no. 2, pp. 94–97, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. Y. H. A. Abdel-Wahab, F. P. M. O'Harte, A. C. Boyd, C. R. Barnett, and P. R. Flatt, “Glycation of insulin results in reduced biological activity in mice,” Acta Diabetologica, vol. 34, no. 4, pp. 265–270, 1997. View at Publisher · View at Google Scholar · View at Scopus
  85. A. C. Boyd, Y. H. A. Abdel-Wahab, A. M. McKillop et al., “Impaired ability of glycated insulin to regulate plasma glucose and stimulate glucose transport and metabolism in mouse abdominal muscle,” Biochimica et Biophysica Acta, vol. 1523, no. 1, pp. 128–134, 2000. View at Publisher · View at Google Scholar · View at Scopus
  86. I. M. Bonapace, R. Addeo, L. Altucci et al., “17β-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation,” Oncogene, vol. 12, no. 4, pp. 753–763, 1996. View at Scopus
  87. B. Corman, M. Duriez, P. Poitevin et al., “Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 3, pp. 1301–1306, 1998. View at Publisher · View at Google Scholar · View at Scopus
  88. T. S. Kern and R. L. Engerman, “Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin,” Diabetes, vol. 50, no. 7, pp. 1636–1642, 2001. View at Scopus
  89. F. Monacelli, A. Poggi, D. Storace et al., “Effects of valsartan therapy on protein glycoxidation,” Metabolism: Clinical and Experimental, vol. 55, no. 12, pp. 1619–1624, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. P. Odetti, C. Pesce, N. Traverso et al., “Comparative trial of N-acetyl-cysteine, taurine, and oxerutin on skin and kidney damage in long-term experimental diabetes,” Diabetes, vol. 52, no. 2, pp. 499–505, 2003. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Ishibashi, T. Matsui, M. Takeuchi, and S. I. Yamagishi, “Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression,” Biochemical and Biophysical Research Communications, vol. 391, no. 3, pp. 1405–1408, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. Y. Ishibashi, T. Matsui, M. Takeuchi, and S. Yamagishi, “Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells,” Hormone and Metabolic Research, vol. 43, no. 10, pp. 731–734, 2011. View at Publisher · View at Google Scholar
  93. T. Matsui, Y. Nishino, M. Takeuchi, and S. I. Yamagishi, “Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis,” Pharmacological Research, vol. 63, no. 5, pp. 383–388, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. Zhan, H. L. Sun, H. Chen et al., “Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis,” Medical Science Monitor, vol. 18, no. 7, pp. BR286–BR291, 2012.
  95. R. Kimura, M. Okouchi, H. Fujioka et al., “Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell apoptosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway,” Neuroscience, vol. 162, no. 4, pp. 1212–1219, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. Y. Ishibashi, Y. Nishino, T. Matsui, M. Takeuchi, and S. Yamagishi, “Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level,” Metabolism, vol. 60, no. 9, pp. 1271–1277, 2011. View at Publisher · View at Google Scholar